ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0867

A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
Abstract Number: 0868

Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Abstract Number: 0869

Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
Abstract Number: 0870

Blood Brain Barrier Integrity and Brain Imaging Patterns in Patients with SLE
Abstract Number: 0871

The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Abstract Number: 0872

Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Abstract Number: 0873

Clinical and Serological Characteristics of Latin American Patients with Lupus Enteritis: A Case-Control Study
Abstract Number: 0874

Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Abstract Number: 0875

Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Abstract Number: 0876

Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Abstract Number: 0877

Association of HCQ Blood Levels with Type 1 and 2 SLE Activity
Abstract Number: 0878

Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Abstract Number: 0879

Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular Risk Impairing the Immune and Cardiovascular Systems
Abstract Number: 0880

Health Information Use by SLE Patients Pre and During COVID-19
Abstract Number: 0881

Economic Evaluation of Neuropsychiatric (NP) Lupus in an International Inception Cohort Using a Multistate Model Approach

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].